Sexual Dysfunctions in Patients Receiving Opioid Agonist Treatment and Heroin-Assisted Treatment Compared to Patients in Private Practice-Identifying Group Differences and Predictors

Maximilian Meyer; Patrick Brunner; Leonie Geissmann; Martin Gürtler; Fabienne Schwager; Rowena Waldis; Marc Vogel; Gerhard A Wiesbeck; Kenneth M Dürsteler

doi:10.3389/fpsyt.2022.846834

Sexual Dysfunctions in Patients Receiving Opioid Agonist Treatment and Heroin-Assisted Treatment Compared to Patients in Private Practice-Identifying Group Differences and Predictors

Front Psychiatry. 2022 Mar 22:13:846834. doi: 10.3389/fpsyt.2022.846834. eCollection 2022.

Authors

Maximilian Meyer¹, Patrick Brunner¹, Leonie Geissmann², Martin Gürtler³, Fabienne Schwager¹, Rowena Waldis¹, Marc Vogel¹, Gerhard A Wiesbeck⁴, Kenneth M Dürsteler^{1

5}

Affiliations

¹ Clinic for Adult Psychiatry, University Psychiatric Clinics, University of Basel, Basel, Switzerland.
² Division of Cognitive Neuroscience, Department of Psychology, University of Basel, Basel, Switzerland.
³ Health Center Allschwil (Gesundheitszentrum Allschwil AG), Allschwil, Switzerland.
⁴ Department of Clinical Research, University of Basel, Basel, Switzerland.
⁵ Department for Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, Zurich, Switzerland.

Abstract

Background and aims: Sexual dysfunctions (SDs) show a marked impact on a person's general wellbeing. Several risk-factors like physical and mental illnesses as well as alcohol and tobacco use have to date been identified to contribute to the occurrence of SDs. The impact of opioid-agonist treatment (OAT) on SDs remains unclear, with some studies demonstrating an improvement after methadone maintenance treatment (MMT) initiation. However, no studies on the prevalence and predictors of SDs in heroin-assisted treatment (HAT) exist to date.

Methods: A cross-sectional study was conducted with patients from a MMT center (n = 57) and a center specializing in HAT (n = 47). A control group of patients with mild transient illnesses (n = 67) was recruited from a general practitioner (GP). The International Index of Erectile Function, the Female Sexual Function Index, as well as measurements for psychological distress, depressive state, nicotine dependence, and high-risk alcohol use were employed. Patients also completed a self-designed questionnaire on help-seeking behavior regarding sexual health. Mann-Whitney-U tests and chi-square tests were performed for group comparisons and binary logistic regression models were calculated.

Results: Twenty-five percent of the GP sample (n = 17), 70.2% (n = 40) of the MMT sample, and 57.4% (n = 27) of the HAT sample suffered from SDs at the time of study conduction. OAT patients differed significantly from GP patients in depressive state, high-risk alcohol use, nicotine dependence, and psychological distress. Age, depressive state, and opioid dependence predicted the occurrence of SDs in the total sample. No differences between OAT and GP patients were found regarding help-seeking behavior.

Discussion: Age, depressive state, and opioid dependence predicted the occurrence of SDs in the total sample. It remains unclear whether SDs are caused by opioid intake itself or result from other substance-use related lifestyle factors, that were not controlled for in this study. A lack of help-seeking behavior was observed in our sample, underlining the importance of clinicians proactively inquiring about the sexual health of their patients.

Conclusion: The high prevalence of SDs observed in MMT does not differ from the prevalence in HAT. Clinicians should actively inquire about their patients' sexual health in GP and OAT centers alike.

Keywords: erectile dysfunction; heroin dependence; opioid dependence; opioid use disorder; sexual dysfunction.